Use of Telehealth for Domiciliary Follow-up After Hematopoietic Cell Transplantation During the COVID-19 Pandemic: Prospective Pilot Study.

COVID-19 SARS-CoV-2 app hematology hematopoietic cell transplantation medical device monitoring mortality stem cell surveillance telemedicine transplant

Journal

JMIR formative research
ISSN: 2561-326X
Titre abrégé: JMIR Form Res
Pays: Canada
ID NLM: 101726394

Informations de publication

Date de publication:
12 Mar 2021
Historique:
received: 28 11 2020
accepted: 16 01 2021
revised: 31 12 2020
pubmed: 19 2 2021
medline: 19 2 2021
entrez: 18 2 2021
Statut: epublish

Résumé

Patients who have recently received a hematopoietic cell transplant (HCT) are at higher risk of acute complications in the first weeks after discharge, especially during the COVID-19 pandemic. The aim of this study was to test the use of a telehealth platform for the follow-up of HCT patients during the first two weeks after discharge. In total, 21 patients who received autologous or allogeneic HCT for hematological malignancies were screened from April 30, 2020, to July 15, 2020. The telehealth platform assisted in the daily collection of vital signs as well as physical and psychological symptoms for two weeks after hospital discharge. The required medical devices (oximeter and blood pressure monitor) were given to patients and a dedicated smartphone app was developed to collect this data. The data were reviewed daily through web-based software by a hematologist specializing in HCT. Only 12 of 21 patients were able to join and complete the study. Technological barriers were the most frequent limiting factor in this study. Among the 12 patients who completed the study, adherence to data reporting was high. The patients' experience of using such a system was considered good. In two cases, the system enabled the early recognition of acute complications. This pilot study showed that telehealth systems can be applied in the early posttransplant setting, with evident advantages for physicians and patients for both medical and psychological aspects. Technological issues still represent a challenge for the applicability of such a system, especially for older adult patients. Easier-to-use technologies could help to expand the use of telehealth systems in this setting in the future.

Sections du résumé

BACKGROUND BACKGROUND
Patients who have recently received a hematopoietic cell transplant (HCT) are at higher risk of acute complications in the first weeks after discharge, especially during the COVID-19 pandemic.
OBJECTIVE OBJECTIVE
The aim of this study was to test the use of a telehealth platform for the follow-up of HCT patients during the first two weeks after discharge.
METHODS METHODS
In total, 21 patients who received autologous or allogeneic HCT for hematological malignancies were screened from April 30, 2020, to July 15, 2020. The telehealth platform assisted in the daily collection of vital signs as well as physical and psychological symptoms for two weeks after hospital discharge. The required medical devices (oximeter and blood pressure monitor) were given to patients and a dedicated smartphone app was developed to collect this data. The data were reviewed daily through web-based software by a hematologist specializing in HCT.
RESULTS RESULTS
Only 12 of 21 patients were able to join and complete the study. Technological barriers were the most frequent limiting factor in this study. Among the 12 patients who completed the study, adherence to data reporting was high. The patients' experience of using such a system was considered good. In two cases, the system enabled the early recognition of acute complications.
CONCLUSIONS CONCLUSIONS
This pilot study showed that telehealth systems can be applied in the early posttransplant setting, with evident advantages for physicians and patients for both medical and psychological aspects. Technological issues still represent a challenge for the applicability of such a system, especially for older adult patients. Easier-to-use technologies could help to expand the use of telehealth systems in this setting in the future.

Identifiants

pubmed: 33600351
pii: v5i3e26121
doi: 10.2196/26121
pmc: PMC7958973
doi:

Types de publication

Journal Article

Langues

eng

Pagination

e26121

Informations de copyright

©Alberto Mussetti, Maria Queralt Salas, Maria Condom, Maite Antonio, Cristian Ochoa, Iulia Ivan, David Jimenez Ruiz-De la Torre, Gabriela Sanz Linares, Belen Ansoleaga, Beatriz Patiño-Gutierrez, Laura Jimenez-Prat, Rocio Parody, Ana Sureda-Balari. Originally published in JMIR Formative Research (http://formative.jmir.org), 12.03.2021.

Références

J Clin Invest. 2020 Dec 1;130(12):6656-6667
pubmed: 32897885
Biol Blood Marrow Transplant. 2020 Jun;26(6):e135-e137
pubmed: 32070723
Lancet Haematol. 2020 Aug;7(8):e564-e565
pubmed: 32450053
Am Soc Clin Oncol Educ Book. 2019 Jan;39:115-121
pubmed: 31099626
JCO Clin Cancer Inform. 2018 Dec;2:1-11
pubmed: 30652590
Lancet Haematol. 2020 Oct;7(10):e737-e745
pubmed: 32798473

Auteurs

Alberto Mussetti (A)

Clinical Hematology Department, Institut Català d'Oncologia-Hospitalet, L'Hospitalet de Llobregat, Barcelona, Spain.
Institut d'Investigació Biomèdica de Bellvitge, Barcelona, Spain.

Maria Queralt Salas (MQ)

Clinical Hematology Department, Institut Català d'Oncologia-Hospitalet, L'Hospitalet de Llobregat, Barcelona, Spain.
Institut d'Investigació Biomèdica de Bellvitge, Barcelona, Spain.

Maria Condom (M)

Clinical Hematology Department, Institut Català d'Oncologia-Hospitalet, L'Hospitalet de Llobregat, Barcelona, Spain.
Institut d'Investigació Biomèdica de Bellvitge, Barcelona, Spain.

Maite Antonio (M)

Institut d'Investigació Biomèdica de Bellvitge, Barcelona, Spain.
Oncohematogeriatrics Unit, Institut Català d'Oncologia-Hospitalet, Barcelona, Spain.

Cristian Ochoa (C)

Institut d'Investigació Biomèdica de Bellvitge, Barcelona, Spain.
Psycho-Oncology Unit, Institut Català d'Oncologia, ICOnnecta't Health Program, Hospital Duran i Reynals, L'Hospitalet de Llobregat, Barcelona, Spain.
Clinical Psychology and Psychobiology Department, Faculty of Psychology, University of Barcelona, Barcelona, Spain.

Iulia Ivan (I)

Clinical Hematology Department, Institut Català d'Oncologia-Hospitalet, L'Hospitalet de Llobregat, Barcelona, Spain.
Institut d'Investigació Biomèdica de Bellvitge, Barcelona, Spain.

David Jimenez Ruiz-De la Torre (D)

Clinical Hematology Department, Institut Català d'Oncologia-Hospitalet, L'Hospitalet de Llobregat, Barcelona, Spain.
Institut d'Investigació Biomèdica de Bellvitge, Barcelona, Spain.

Gabriela Sanz Linares (G)

Clinical Hematology Department, Institut Català d'Oncologia-Hospitalet, L'Hospitalet de Llobregat, Barcelona, Spain.
Institut d'Investigació Biomèdica de Bellvitge, Barcelona, Spain.

Belen Ansoleaga (B)

Clinical Hematology Department, Institut Català d'Oncologia-Hospitalet, L'Hospitalet de Llobregat, Barcelona, Spain.
Institut d'Investigació Biomèdica de Bellvitge, Barcelona, Spain.

Beatriz Patiño-Gutierrez (B)

Clinical Hematology Department, Institut Català d'Oncologia-Hospitalet, L'Hospitalet de Llobregat, Barcelona, Spain.

Laura Jimenez-Prat (L)

Clinical Hematology Department, Institut Català d'Oncologia-Hospitalet, L'Hospitalet de Llobregat, Barcelona, Spain.

Rocio Parody (R)

Clinical Hematology Department, Institut Català d'Oncologia-Hospitalet, L'Hospitalet de Llobregat, Barcelona, Spain.
Institut d'Investigació Biomèdica de Bellvitge, Barcelona, Spain.

Ana Sureda-Balari (A)

Clinical Hematology Department, Institut Català d'Oncologia-Hospitalet, L'Hospitalet de Llobregat, Barcelona, Spain.
Institut d'Investigació Biomèdica de Bellvitge, Barcelona, Spain.

Classifications MeSH